ofloxacin and Pelvic Inflammatory Disease studies

Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.
ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.

Pelvic Inflammatory Disease: A spectrum of inflammation involving the female upper genital tract and the supporting tissues. It is usually caused by an ascending infection of organisms from the endocervix. Infection may be confined to the uterus (ENDOMETRITIS), the FALLOPIAN TUBES; (SALPINGITIS); the ovaries (OOPHORITIS), the supporting ligaments (PARAMETRITIS), or may involve several of the above uterine appendages. Such inflammation can lead to functional impairment and infertility.

Research Excerpts

Excerpt	Relevance	Reference
"A multicentre, randomised non-inferiority trial compared the efficacy and safety of 14 days of ofloxacin and metronidazole (standard-of-care (SoC)) versus a single dose of intramuscular ceftriaxone followed by 5 days of azithromycin and metronidazole (intervention arm (IA)) in women with mild-to-moderate pelvic inflammatory disease (PID)."	9.41	Treatment of mild-to-moderate pelvic inflammatory disease with a short-course azithromycin-based regimen versus ofloxacin plus metronidazole: results of a multicentre, randomised controlled trial. ( Dean, G; Pitt, R; Ross, J; Sabin, C; Soni, S; Whetham, J, 2021)
"To evaluate the efficacy and safety of moxifloxacin versus ofloxacin plus metronidazole in patients with uncomplicated pelvic inflammatory disease (uPID; defined as PID symptoms and signs, but no complications such as septicemia, perihepatitis, and tubo-ovarian abscess) in Turkey."	9.17	Single daily dose of moxifloxacin versus ofloxacin plus metronidazole as a new treatment approach to uncomplicated pelvic inflammatory disease: a multicentre prospective randomized trial. ( Ark, C; Aşicioğlu, O; Ertas, IE; Gungorduk, K; Ozdemir, A; Sanci, M; Yildirim, G, 2013)
"To evaluate the efficacy and safety of moxifloxacin versus levofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease (uPID) in Asia."	9.14	Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. ( Arvis, P; Hampel, B; Judlin, P; Liao, Q; Liu, Z; Reimnitz, P, 2010)
"This multinational, multicentre, prospective, randomised, double blind, parallel group, non-inferiority study compared the efficacy and safety of moxifloxacin monotherapy with ofloxacin plus metronidazole in women with uncomplicated pelvic inflammatory disease."	9.12	Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial. ( Alefelder, M; Arvis, P; Cronjé, HS; Kureishi, A; Paszkowski, T; Rakoczi, I; Reimnitz, P; Ross, JD; Vildaite, D, 2006)
"A multicenter randomized comparative trial was done to assess the safety and efficacy of oral ofloxacin (400 mg twice daily for 10 days) versus cefoxitin (2 g intramuscularly) followed by doxycycline (100 mg twice daily orally for 10 days) for the outpatient treatment of uncomplicated pelvic inflammatory disease (PID)."	9.07	Multicenter randomized trial of ofloxacin versus cefoxitin and doxycycline in outpatient treatment of pelvic inflammatory disease. Ambulatory PID Research Group. ( Berkeley, A; Binder, D; Faro, S; Gordon, S; Martens, MG; Yarborough, DR, 1993)
"Large randomized controlled trials support the efficacy of moxifloxacin for the treatment of uncomplicated pelvic inflammatory disease (PID)."	7.76	A comparison of treatment outcomes for moxifloxacin versus ofloxacin/metronidazole for first-line treatment of uncomplicated non-gonococcal pelvic inflammatory disease. ( Boothby, M; Page, J; Pryor, R; Ross, JD, 2010)
"We attempted to define the microbiologic characteristics of acute salpingitis in women presenting to an urban emergency department with pelvic inflammatory disease and to determine the effectiveness of ofloxacin in treating this disease."	7.68	Microbial etiology of urban emergency department acute salpingitis: treatment with ofloxacin. ( Brockwell, NJ; Dalton, HP; Soper, DE, 1992)
"Uncomplicated pelvic inflammatory disease (PID) is a common disease caused by numerous pathogens: sexually transmitted infections (such as Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium), anaerobes, and other organisms from the vaginal flora."	6.74	Levofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: a preliminary study. ( Judlin, P; Thiebaugeorges, O, 2009)
"Sexually transmitted diseases are an important cause of morbidity in women."	6.38	The clinical experience with ofloxacin in the treatment of sexually transmitted diseases. ( Corrado, ML, 1991)
"A multicentre, randomised non-inferiority trial compared the efficacy and safety of 14 days of ofloxacin and metronidazole (standard-of-care (SoC)) versus a single dose of intramuscular ceftriaxone followed by 5 days of azithromycin and metronidazole (intervention arm (IA)) in women with mild-to-moderate pelvic inflammatory disease (PID)."	5.41	Treatment of mild-to-moderate pelvic inflammatory disease with a short-course azithromycin-based regimen versus ofloxacin plus metronidazole: results of a multicentre, randomised controlled trial. ( Dean, G; Pitt, R; Ross, J; Sabin, C; Soni, S; Whetham, J, 2021)
"To evaluate the efficacy and safety of moxifloxacin versus ofloxacin plus metronidazole in patients with uncomplicated pelvic inflammatory disease (uPID; defined as PID symptoms and signs, but no complications such as septicemia, perihepatitis, and tubo-ovarian abscess) in Turkey."	5.17	Single daily dose of moxifloxacin versus ofloxacin plus metronidazole as a new treatment approach to uncomplicated pelvic inflammatory disease: a multicentre prospective randomized trial. ( Ark, C; Aşicioğlu, O; Ertas, IE; Gungorduk, K; Ozdemir, A; Sanci, M; Yildirim, G, 2013)
"To evaluate the efficacy and safety of moxifloxacin versus levofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease (uPID) in Asia."	5.14	Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. ( Arvis, P; Hampel, B; Judlin, P; Liao, Q; Liu, Z; Reimnitz, P, 2010)
"This multinational, multicentre, prospective, randomised, double blind, parallel group, non-inferiority study compared the efficacy and safety of moxifloxacin monotherapy with ofloxacin plus metronidazole in women with uncomplicated pelvic inflammatory disease."	5.12	Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial. ( Alefelder, M; Arvis, P; Cronjé, HS; Kureishi, A; Paszkowski, T; Rakoczi, I; Reimnitz, P; Ross, JD; Vildaite, D, 2006)
"A multicenter randomized comparative trial was done to assess the safety and efficacy of oral ofloxacin (400 mg twice daily for 10 days) versus cefoxitin (2 g intramuscularly) followed by doxycycline (100 mg twice daily orally for 10 days) for the outpatient treatment of uncomplicated pelvic inflammatory disease (PID)."	5.07	Multicenter randomized trial of ofloxacin versus cefoxitin and doxycycline in outpatient treatment of pelvic inflammatory disease. Ambulatory PID Research Group. ( Berkeley, A; Binder, D; Faro, S; Gordon, S; Martens, MG; Yarborough, DR, 1993)
"Large randomized controlled trials support the efficacy of moxifloxacin for the treatment of uncomplicated pelvic inflammatory disease (PID)."	3.76	A comparison of treatment outcomes for moxifloxacin versus ofloxacin/metronidazole for first-line treatment of uncomplicated non-gonococcal pelvic inflammatory disease. ( Boothby, M; Page, J; Pryor, R; Ross, JD, 2010)
"We attempted to define the microbiologic characteristics of acute salpingitis in women presenting to an urban emergency department with pelvic inflammatory disease and to determine the effectiveness of ofloxacin in treating this disease."	3.68	Microbial etiology of urban emergency department acute salpingitis: treatment with ofloxacin. ( Brockwell, NJ; Dalton, HP; Soper, DE, 1992)
"Uncomplicated pelvic inflammatory disease (PID) is a common disease caused by numerous pathogens: sexually transmitted infections (such as Chlamydia trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium), anaerobes, and other organisms from the vaginal flora."	2.74	Levofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: a preliminary study. ( Judlin, P; Thiebaugeorges, O, 2009)
"Ofloxacin was used in the complex therapy of acute inflammatory diseases of the uterus and uterine appendages."	2.68	[Comparative evaluation of the effectiveness of ofloxacin in comprehensive treatment of acute inflammatory diseases of the uterus and uterine appendages]. ( Denisova, EN; Evseev, AA; Savel'eva, GM, 1996)
"Ofloxacin tablets were given to 149 women and 159 women received placebo tablets."	2.67	No effect of single dose ofloxacin on postoperative infection rate after first-trimester abortion. A clinical, controlled trial. ( Engdahl, E; Larsen, T; Nielsen, IK, 1993)
"Ofloxacin is a new quinolone-carboxylic acid derivative with a broad spectrum of activity, excellent bioavailability after oral administration and insignificant metabolisation."	2.66	[Summarized results of clinical phase II and III studies with ofloxacin (HOE 280) in Europe]. ( Blomer, R; Bruch, K; Zahlten, RN, 1986)
"Treatment of pelvic inflammatory disease (PID) should provide high rates of clinical and microbiological cure for a range of pathogens and should ultimately prevent reproductive morbidity."	2.44	Newest approaches to treatment of pelvic inflammatory disease: a review of recent randomized clinical trials. ( Haggerty, CL; Ness, RB, 2007)
"Sexually transmitted diseases are an important cause of morbidity in women."	2.38	The clinical experience with ofloxacin in the treatment of sexually transmitted diseases. ( Corrado, ML, 1991)
"Most patients (81%) with pelvic inflammatory disease were diagnosed as having chlamydia alone."	1.48	Gonococcal and Chlamydial Cases of Pelvic Inflammatory Disease at 2 Canadian Sexually Transmitted Infection Clinics, 2004 to 2014: A Retrospective Cross-sectional Review. ( Chen, JZ; Gratrix, J; Parker, P; Read, R; Singh, AE; Smyczek, P, 2018)
"Actinomycosis is a rare disease."	1.34	[Pelvic and abdominal actinomycosis presenting as a parietal mass]. ( Bory, AM; Chevalier-Evain, V; Mubiayi, N; Orazi, G; Therby, D, 2007)

Research

Studies (25)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Bacteriological Response at Follow-up Visit in Intent To Treat Population With Causative Organism

Timeframe	Studies, this research(%)	All Research%
pre-1990	1 (4.00)	18.7374
1990's	8 (32.00)	18.2507
2000's	8 (32.00)	29.6817
2010's	7 (28.00)	24.3611
2020's	1 (4.00)	2.80

Authors	Studies
Dean, G	1
Soni, S	1
Pitt, R	1
Ross, J	1
Sabin, C	1
Whetham, J	1
Chen, JZ	1
Gratrix, J	1
Smyczek, P	1
Parker, P	1
Read, R	1
Singh, AE	1
Woods, JL	1
Scurlock, AM	1
Hensel, DJ	1
Aşicioğlu, O	1
Gungorduk, K	1
Ozdemir, A	1
Ertas, IE	1
Yildirim, G	1
Sanci, M	1
Ark, C	1
Brun, JL	2
Graesslin, O	1
Fauconnier, A	2
Verdon, R	1
Agostini, A	1
Bourret, A	2
Derniaux, E	1
Garbin, O	1
Huchon, C	1
Lamy, C	1
Quentin, R	1
Judlin, P	3
Haggerty, CL	2
Ness, RB	3
Thiebaugeorges, O	1
Boothby, M	1
Page, J	1
Pryor, R	1
Ross, JD	2
Liao, Q	1
Liu, Z	1
Reimnitz, P	2
Hampel, B	1
Arvis, P	2
Hall, CE	1
Keegan, H	1
Rogstad, KE	1
Cronjé, HS	1
Paszkowski, T	1
Rakoczi, I	1
Vildaite, D	1
Kureishi, A	1
Alefelder, M	1
Deng, JY	1
Tovar, JM	1
Mubiayi, N	1
Bory, AM	1
Orazi, G	1
Chevalier-Evain, V	1
Therby, D	1
Smith, KJ	1
Wiesenfeld, HC	1
Roberts, MS	1
Verhoest, P	1
Fernandez, H	1
Henry-Suchet, J	1
Orfila, J	1
Boulanger, JC	1
Nielsen, IK	1
Engdahl, E	1
Larsen, T	1
Martens, MG	1
Gordon, S	1
Yarborough, DR	1
Faro, S	1
Binder, D	1
Berkeley, A	1
Savel'eva, GM	1
Evseev, AA	1
Denisova, EN	1
Chimura, T	1
Morisaki, N	1
Funayama, T	1
Oda, T	1
Soper, DE	1
Brockwell, NJ	1
Dalton, HP	1
Corrado, ML	1
Blomer, R	1
Bruch, K	1
Zahlten, RN	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
[NCT01799356]	Phase 4	1,303 participants (Actual)	Interventional	2010-06-30	Completed
A Prospective, Randomized, Double Dummy, Double Blind, Multi-center Multinational Trial Comparing the Efficacy and Safety of Moxifloxacin 400 mg PO QD 24 Hours for 14 Days to That of Levofloxacin 500 mg PO QD 24 Hours Plus Metronidazole 500 mg BID for 14 [NCT00453349]	Phase 3	460 participants (Actual)	Interventional	2007-01-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Subjects with at least one causative organism identified in the pre-therapy culture or a positive pre-therapy PCR result and an appropriate post-therapy bacteriological evaluation available were analyzed. Bacteriological responses at follow-up visit was analyzed exploratively in the same way as the primary efficacy variable. (NCT00453349)
Timeframe: 28 - 42 days after completion of study drug therapy

Bacteriological Response at Follow-up Visit Microbiologically Valid

Intervention	participants (Number)
	Eradication	Eradication with recurrence, persistence
Levofloxacin Plus Metronidazole	23	11
Moxifloxacin	23	13

Bacteriological Response at Test Of Cure (TOC) Visit in Intent To Treat Population With Causative Organism

Intervention	participants (Number)
	Eradication	Eradication with recurrence, persistence
Levofloxacin Plus Metronidazole	22	4
Moxifloxacin	23	5

Bacteriological response at the TOC was analyzed exploratively in the same way as the primary efficacy variable based on the subgroup of microbiologically valid subjects. At the TOC visit, eradication was considered a bacteriological success, and persistence, presumed persistence and superinfection were considered bacteriological failures. (NCT00453349)
Timeframe: 7 - 14 days at TOC visit

Bacteriological Response at Test Of Cure (TOC) Visit Microbiologically Valid

Intervention	participants (Number)
	Eradication	Persistence, indeterminate, missing
Levofloxacin Plus Metronidazole	25	9
Moxifloxacin	28	8

The bacteriological responses was based on the results of appropriate cultures taken before and, if necessary, during treatment, at the TOC visit and within the follow-up period. Bacteriological response at the TOC visit would also be based on repeated PCR tests for N. gonorrhoeae and C. trachomatis. (NCT00453349)
Timeframe: 7 - 14 days at TOC visit

Clinical Response 7 to 14 Days After Completion of Study Drug Therapy in Per Protocol (PP) Population

Intervention	participants (Number)
	Eradication	Persistence
Levofloxacin Plus Metronidazole	22	4
Moxifloxacin	27	3

Clinical cure was defined as: Reduction of the tenderness score (modified McCormack) by > 70% and apyrexia (rectal/tympanic/oral temperature value < 38.0°C or axillary temperature value < 37.5°C) and white blood cell count < 10,500/mm^3. (NCT00453349)
Timeframe: 7 - 14 days after completion of study drug therapy

Clinical Response 7 to 14 Days After Completion of Study Drug Therapy on Intent To Treat (ITT) Population

Intervention	participants (Number)
	Clinical cure	Clinical non-success
Levofloxacin Plus Metronidazole	155	35
Moxifloxacin	152	42

"For any subject in the ITT population also valid for the PP analysis, same clinical response as in the PP analysis was applied to the ITT analysis. For those subjects in the ITT population invalid for the PP analysis, any clinical response different from clinical cure was set to non-success." (NCT00453349)
Timeframe: 7 - 14 days after completion of study drug therapy

Clinical Response at Follow-up Visit on Intent To Treat Population

Intervention	participants (Number)
	Clinical cure	Clinical non-success
Levofloxacin Plus Metronidazole	171	59
Moxifloxacin	163	62

"All successfully treated subjects and subjects evaluated asindeterminate at TOC, who were not administered an additional antibiotic therapy would have their clinical response rate assessed at the follow-up visit. Patients with missing or indeterminate outcome were treated as non-successes." (NCT00453349)
Timeframe: 28 - 42 days after completion of study drug therapy

Clinical Response at Follow-up Visit on Per Protocol Population

Intervention	participants (Number)
	Continued clinical cure	Failure, relapse, indeterminate, missing
Levofloxacin Plus Metronidazole	170	60
Moxifloxacin	166	59

Clinical response at follow up was analyzed exploratively in the same way as the primary efficacy variable. At Follow-up, the clinical response was graded as continued cure, clinical relapse, or indeterminate, of which only continued cure was considered success. Failures from end of treatment were carried forward. (NCT00453349)
Timeframe: 28 - 42 days after completion of study drug therapy

Clinical Response on Treatment for Intent To Treat Population

Intervention	participants (Number)
	Continued clinical cure	Continued failure, clinical recurrence/relapse
Levofloxacin Plus Metronidazole	158	22
Moxifloxacin	157	27

Clinical response during treatment was analyzed exploratively in the same way as the primary efficacy variable. At the During Therapy (Day 4 to 7) assessment, the clinical response was graded as clinical Improvement, clinical failure or indeterminate accordingly. Clinical improvement was considered success, all other outcomes as non-success. (NCT00453349)
Timeframe: 4 - 7 days after start of therapy

Clinical Response on Treatment for Per Protocol Population

Intervention	participants (Number)
	Clinical improvement	Failure, indeterminate, missing
Levofloxacin Plus Metronidazole	170	60
Moxifloxacin	166	59

At the During Therapy (Day 4 to 7) assessment, the clinical response was graded as clinical Improvement (severity score reduced by >30% with improvement in temperature, clinical failure (reduction in severity score of < or equal 30% and/or no improvement in temperature) or indeterminate (clinical assessment not possible to determine). (NCT00453349)
Timeframe: 4 - 7 days after start of therapy

Number of Subjects Who Received Alternative Medicine

Intervention	participants (Number)
	Clinical Improvement	Clinical failure
Levofloxacin Plus Metronidazole	181	5
Moxifloxacin	177	11

As alternative medicine any systemic antibacterial medication was considered. (NCT00453349)
Timeframe: Up to 42 days after end of treatment

Article	Year
Updated French guidelines for diagnosis and management of pelvic inflammatory disease. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2016, Volume: 134, Issue:2 Topics: Anti-Infective Agents; Ceftriaxone; Disease Management; Drug Therapy, Combination; Female; France; H	2016
Diagnosis and treatment of pelvic inflammatory disease. Women's health (London, England), 2008, Volume: 4, Issue:4 Topics: Adult; Anti-Bacterial Agents; Azithromycin; Chlamydia trachomatis; Female; Humans; Infertility, Fema	2008
[Management of uncomplicated pelvic inflammatory disease]. Journal de gynecologie, obstetrique et biologie de la reproduction, 2012, Volume: 41, Issue:8 Topics: Anti-Bacterial Agents; Azithromycin; Ceftriaxone; Chlamydia trachomatis; Drug Resistance, Microbial;	2012
Newest approaches to treatment of pelvic inflammatory disease: a review of recent randomized clinical trials. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2007, Apr-01, Volume: 44, Issue:7 Topics: Anti-Bacterial Agents; Aza Compounds; Azithromycin; Ciprofloxacin; Clindamycin; Dose-Response Relati	2007
The clinical experience with ofloxacin in the treatment of sexually transmitted diseases. American journal of obstetrics and gynecology, 1991, Volume: 164, Issue:5 Pt 2 Topics: Chlamydia Infections; Chlamydia trachomatis; Female; Gonorrhea; Humans; Ofloxacin; Pelvic Inflammato	1991

Article	Year
Treatment of mild-to-moderate pelvic inflammatory disease with a short-course azithromycin-based regimen versus ofloxacin plus metronidazole: results of a multicentre, randomised controlled trial. Sexually transmitted infections, 2021, Volume: 97, Issue:3 Topics: Adolescent; Adult; Anti-Bacterial Agents; Azithromycin; Drug Therapy, Combination; Female; Humans; M	2021
Single daily dose of moxifloxacin versus ofloxacin plus metronidazole as a new treatment approach to uncomplicated pelvic inflammatory disease: a multicentre prospective randomized trial. European journal of obstetrics, gynecology, and reproductive biology, 2013, Volume: 171, Issue:1 Topics: Adolescent; Adult; Aza Compounds; Drug Therapy, Combination; Female; Fluoroquinolones; Humans; Metro	2013
Levofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: a preliminary study. European journal of obstetrics, gynecology, and reproductive biology, 2009, Volume: 145, Issue:2 Topics: Adult; Anti-Bacterial Agents; Chlamydia Infections; Female; Humans; Levofloxacin; Metronidazole; Ofl	2009
Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG : an international journal of obstetrics and gynaecology, 2010, Volume: 117, Issue:12 Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Double-Blind Method; Drug Therapy, Co	2010
Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG : an international journal of obstetrics and gynaecology, 2010, Volume: 117, Issue:12 Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Double-Blind Method; Drug Therapy, Co	2010
Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG : an international journal of obstetrics and gynaecology, 2010, Volume: 117, Issue:12 Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Double-Blind Method; Drug Therapy, Co	2010
Efficacy and safety of moxifloxacin in uncomplicated pelvic inflammatory disease: the MONALISA study. BJOG : an international journal of obstetrics and gynaecology, 2010, Volume: 117, Issue:12 Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Aza Compounds; Double-Blind Method; Drug Therapy, Co	2010
Moxifloxacin versus ofloxacin plus metronidazole in uncomplicated pelvic inflammatory disease: results of a multicentre, double blind, randomised trial. Sexually transmitted infections, 2006, Volume: 82, Issue:6 Topics: Administration, Oral; Adult; Anti-Infective Agents; Aza Compounds; Double-Blind Method; Drug Therapy	2006
[A new therapeutic strategy using a ofloxacin-amoxicillin-clavulanic acid combination in the treatment of upper gynecologic infections. Apropos of 123 cases]. Journal de gynecologie, obstetrique et biologie de la reproduction, 1994, Volume: 23, Issue:1 Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Bacterial Infections; beta-Lactamase Inhibito	1994
No effect of single dose ofloxacin on postoperative infection rate after first-trimester abortion. A clinical, controlled trial. Acta obstetricia et gynecologica Scandinavica, 1993, Volume: 72, Issue:7 Topics: Abortion, Induced; Administration, Oral; Adult; Double-Blind Method; Female; Humans; Ofloxacin; Pelv	1993
Multicenter randomized trial of ofloxacin versus cefoxitin and doxycycline in outpatient treatment of pelvic inflammatory disease. Ambulatory PID Research Group. Southern medical journal, 1993, Volume: 86, Issue:6 Topics: Adolescent; Adult; Ambulatory Care; Cefoxitin; Chlamydia Infections; Chlamydia trachomatis; Doxycycl	1993
[Comparative evaluation of the effectiveness of ofloxacin in comprehensive treatment of acute inflammatory diseases of the uterus and uterine appendages]. Antibiotiki i khimioterapiia = Antibiotics and chemoterapy [sic], 1996, Volume: 41, Issue:9 Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Anti-Bacterial Agents; Anti-Infective Agents	1996
[Summarized results of clinical phase II and III studies with ofloxacin (HOE 280) in Europe]. Infection, 1986, Volume: 14 Suppl 1 Topics: Anti-Infective Agents; Bacterial Infections; Clinical Trials as Topic; Drug Evaluation; Drug Resista	1986

Article	Year
Gonococcal and Chlamydial Cases of Pelvic Inflammatory Disease at 2 Canadian Sexually Transmitted Infection Clinics, 2004 to 2014: A Retrospective Cross-sectional Review. Sexually transmitted diseases, 2018, Volume: 45, Issue:4 Topics: Adolescent; Adult; Ambulatory Care Facilities; Anti-Bacterial Agents; Canada; Chlamydia Infections;	2018
Pelvic inflammatory disease in the adolescent: understanding diagnosis and treatment as a health care provider. Pediatric emergency care, 2013, Volume: 29, Issue:6 Topics: Adolescent; Anti-Bacterial Agents; Arkansas; Ceftriaxone; Centers for Disease Control and Prevention	2013
A comparison of treatment outcomes for moxifloxacin versus ofloxacin/metronidazole for first-line treatment of uncomplicated non-gonococcal pelvic inflammatory disease. International journal of STD & AIDS, 2010, Volume: 21, Issue:3 Topics: Adolescent; Adult; Anti-Infective Agents; Aza Compounds; Drug Therapy, Combination; Female; Fluoroqu	2010
Psychiatric side effects of ofloxacin used in the treatment of pelvic inflammatory disease. International journal of STD & AIDS, 2003, Volume: 14, Issue:9 Topics: Adult; Anti-Infective Agents; Anxiety Disorders; Depression; Female; Humans; Ofloxacin; Pelvic Infla	2003
Pancytopenia with levofloxacin therapy for pelvic inflammatory disease in an otherwise healthy young patient. The Annals of pharmacotherapy, 2006, Volume: 40, Issue:9 Topics: Adult; Female; Humans; Levofloxacin; Ofloxacin; Pancytopenia; Pelvic Inflammatory Disease	2006
[Pelvic and abdominal actinomycosis presenting as a parietal mass]. Presse medicale (Paris, France : 1983), 2007, Volume: 36, Issue:3 Pt 1 Topics: Abdominal Abscess; Abdominal Wall; Actinomycosis; Amikacin; Amoxicillin; Anti-Bacterial Agents; Biop	2007
Cost-effectiveness of alternative outpatient pelvic inflammatory disease treatment strategies. Sexually transmitted diseases, 2007, Volume: 34, Issue:12 Topics: Ambulatory Care; Anti-Bacterial Agents; Cost-Benefit Analysis; Doxycycline; Drug Therapy, Combinatio	2007
National guideline for the management of pelvic infection and perihepatitis. Clinical Effectiveness Group (Association of Genitourinary Medicine and the Medical Society for the Study of Venereal Diseases). Sexually transmitted infections, 1999, Volume: 75 Suppl 1 Topics: Anti-Bacterial Agents; Cefoxitin; Ceftriaxone; Ciprofloxacin; Clindamycin; Contact Tracing; Female;	1999
[Levofloxacin in obstetrics and gynecology]. The Japanese journal of antibiotics, 1992, Volume: 45, Issue:5 Topics: Adult; Drug Evaluation; Endometritis; Female; Humans; Levofloxacin; Middle Aged; Ofloxacin; Pelvic I	1992
Microbial etiology of urban emergency department acute salpingitis: treatment with ofloxacin. American journal of obstetrics and gynecology, 1992, Volume: 167, Issue:3 Topics: Acute Disease; Adult; Chlamydia Infections; Emergency Medical Services; Female; Follow-Up Studies; G	1992

ofloxacin and Pelvic Inflammatory Disease